Bionano Genomics Launches $10M Equity Offering Amid Going Concern Warning

TL;DR

**BNGO is scrambling for cash with a dilutive offering, signaling deep financial distress and a high-stakes bet on future OGM adoption.**

AI Summary

Bionano Genomics, Inc. (BNGO) is offering up to 2,032,520 shares of common stock, along with Series E and Series F warrants, at an assumed combined public offering price of $4.92 per share. Additionally, the company is offering up to 2,032,520 pre-funded warrants at an assumed combined price of $4.9199, targeting purchasers who would otherwise exceed 4.99% (or 9.99%) beneficial ownership. This offering, which will terminate on October 11, 2025, aims to raise capital, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent, receiving a 6.0% cash fee and a 0.5% management fee. The company explicitly states it needs to obtain significant additional financing to fund its strategic plans and commercialization efforts, and manage costs to continue as a going concern within 12 months of its June 30, 2025, Quarterly Report on Form 10-Q. The S-1 filing highlights risks including the ability to improve margins, extend cash runway, and achieve profitability, alongside the need for OGM adoption and the impact of Category I CPT codes. The offering is structured without a minimum requirement, meaning actual proceeds may be substantially less than the maximum. The closing price of BNGO common stock on September 10, 2025, was $4.92 per share.

Why It Matters

This S-1 filing signals Bionano Genomics' urgent need for capital, explicitly stating the company's ability to continue as a going concern within 12 months is dependent on securing significant additional financing. For investors, this offering, which could dilute existing shareholders, represents a critical lifeline or a potential red flag, depending on the market's reception and the company's ability to execute its strategic plans. Employees and customers will be watching closely for signs of financial stability, as the company operates in the competitive genomic analysis market, vying with established players and emerging technologies. The success of this offering and the subsequent deployment of capital will determine BNGO's capacity to drive adoption of its Optical Genome Mapping (OGM) technology and compete effectively.

Risk Assessment

Risk Level: high — The S-1 explicitly states Bionano Genomics' 'ability to continue as a going concern within 12 months of the filing of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which requires us to manage costs and obtain significant additional financing.' This direct admission of going concern risk, coupled with the dilutive nature of the offering (up to 2,032,520 shares of common stock and 6,097,560 shares issuable upon warrant exercise), indicates a precarious financial position.

Analyst Insight

Investors should approach BNGO with extreme caution, recognizing the significant going concern risk and potential for further dilution. Monitor the actual proceeds from this offering and subsequent financial reports for evidence of improved cash runway and progress towards profitability. Consider the long-term viability of OGM adoption against the company's immediate financial challenges.

Key Numbers

• 2,032,520 — Shares of Common Stock (Maximum number of shares offered in the public offering)
• 2,032,520 — Pre-Funded Warrants (Maximum number of Pre-Funded Warrants offered)
• 6,097,560 — Shares of Common Stock Issuable (Total shares issuable upon exercise of all Warrants and Pre-Funded Warrants)
• $4.92 — Assumed Offering Price (Assumed combined public offering price per share and accompanying Warrants, equal to the closing price on September 10, 2025)
• $0.0001 — Pre-Funded Warrant Exercise Price (Exercise price per share for each Pre-Funded Warrant)
• 6.0% — Placement Agent Cash Fee (Percentage of aggregate gross proceeds paid to H.C. Wainwright & Co., LLC)
• 0.5% — Placement Agent Management Fee (Percentage of aggregate gross proceeds paid to H.C. Wainwright & Co., LLC)
• $50,000 — Non-Accountable Expenses (Maximum reimbursement for placement agent's non-accountable expenses)
• $100,000 — Legal and Out-of-Pocket Expenses (Maximum reimbursement for placement agent's legal and other out-of-pocket expenses)
• 12 months — Going Concern Period (Period within which Bionano Genomics needs to secure financing to continue as a going concern from June 30, 2025)

Key Players & Entities

• Bionano Genomics, Inc. (company) — Registrant and issuer of securities
• H.C. Wainwright & Co., LLC (company) — Exclusive placement agent for the offering
• R. Erik Holmlin, Ph.D. (person) — President and Chief Executive Officer of Bionano Genomics, Inc.
• Nasdaq Capital Market (regulator) — Listing exchange for BNGO common stock
• $4.92 (dollar_amount) — Assumed combined public offering price per share and accompanying Warrants, and closing price on September 10, 2025
• $4.9199 (dollar_amount) — Assumed combined public offering price per Pre-Funded Warrant and accompanying Warrants
• 6.0% (dollar_amount) — Cash fee percentage paid to placement agent
• 0.5% (dollar_amount) — Management fee percentage paid to placement agent
• October 11, 2025 (date) — Termination date for the offering
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing

FAQ

Risk Factors

• Going Concern and Need for Additional Financing [high — financial]: The company explicitly states it needs to obtain significant additional financing to fund its strategic plans and commercialization efforts, and manage costs to continue as a going concern within 12 months of its June 30, 2025, Quarterly Report on Form 10-Q. Failure to secure this financing could jeopardize its ability to continue operations.
• Dependence on OGM Adoption and Market Acceptance [high — operational]: The success of Bionano Genomics is heavily reliant on the widespread adoption of its Optical Genome Mapping (OGM) technology. The company faces challenges in convincing the market to adopt its novel technology over established methods, which could limit revenue growth and market penetration.
• Impact of Category I CPT Codes [medium — regulatory]: The S-1 filing highlights the importance of obtaining Category I CPT codes for reimbursement. The absence or delay in obtaining these codes can significantly impact the company's ability to generate revenue from its diagnostic tests and services, as it affects payer coverage and patient access.
• Ability to Improve Margins and Extend Cash Runway [high — financial]: The company acknowledges the need to improve its gross margins and extend its cash runway. Current operational costs and pricing strategies may not be sustainable without significant improvements, increasing the risk of running out of capital before achieving profitability.
• Competition and Technological Obsolescence [medium — market]: The genomics market is highly competitive, with established players and emerging technologies. Bionano Genomics faces the risk of its OGM technology being surpassed by newer, more efficient, or cost-effective solutions, or failing to gain a competitive edge against existing methods.
• Uncertainty of Offering Proceeds [medium — financial]: The offering is structured without a minimum requirement, meaning actual proceeds could be substantially less than the maximum target of approximately $10 million (based on 2,032,520 shares at $4.92). This uncertainty impacts the company's ability to rely on the full amount for its strategic plans.

Industry Context

The genomics industry is characterized by rapid technological advancements and intense competition. Bionano Genomics operates in the specialized area of structural variation detection using its OGM technology, aiming to differentiate itself from traditional methods like karyotyping and SNP arrays. Key trends include the increasing demand for advanced diagnostics, personalized medicine, and the integration of genomic data into clinical workflows.

Regulatory Implications

The company's success is significantly tied to regulatory approvals and reimbursement pathways. Obtaining Category I CPT codes is critical for widespread adoption and revenue generation, as it impacts insurance coverage for its OGM-based tests. Navigating these regulatory hurdles is a key challenge.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Assess OGM adoption rates and market penetration.
3. Evaluate progress on CPT code acquisition and reimbursement.
4. Analyze gross margin improvement initiatives.

Key Dates

• 2025-06-30: Quarterly Report on Form 10-Q filed — Established the 12-month going concern period, highlighting the immediate need for financing.
• 2025-09-10: Closing price of BNGO common stock — The closing price of $4.92 per share was used as the assumed combined public offering price, setting the valuation basis for the current offering.
• 2025-10-11: Termination date of the offering — Sets the deadline for the company to complete its capital raise through this S-1 filing.

Glossary

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If a company is deemed not to be a going concern, it raises doubts about its ability to meet its obligations. (Bionano Genomics explicitly states it needs financing to continue as a going concern within 12 months, indicating significant financial distress.)

Pre-funded Warrant

A type of warrant that allows the holder to purchase a share of common stock at a nominal exercise price (e.g., $0.0001). These are often used in offerings to allow certain investors to acquire shares without immediately triggering beneficial ownership thresholds. (Used in this offering to accommodate investors who may exceed ownership limits, impacting the structure of the capital raise.)

Category I CPT Codes

Current Procedural Terminology (CPT) codes are used for billing and reimbursement purposes by healthcare providers. Category I codes represent procedures and services that are widely accepted and used. (Crucial for Bionano Genomics' revenue generation, as obtaining these codes facilitates insurance reimbursement for its diagnostic tests.)

Optical Genome Mapping (OGM)

A technology developed by Bionano Genomics that provides a high-resolution view of the entire genome, enabling the detection of large structural variations. (This is Bionano's core technology, and its market adoption is critical for the company's success and revenue.)

Cash Runway

The amount of time a company can continue to operate before it runs out of cash, assuming current spending rates. (The company's ability to extend its cash runway is a key concern, directly linked to its going concern status and need for financing.)

Year-Over-Year Comparison

This S-1 filing indicates a critical juncture for Bionano Genomics, highlighting a significant need for additional financing to address its going concern status within the next 12 months. Unlike previous filings that may have focused on technology development and early-stage commercialization, this document emphasizes the immediate financial pressures and the reliance on the current offering to extend its cash runway. Key risks related to market adoption of OGM and reimbursement pathways remain, but the urgency of securing capital is a more pronounced theme.

Key Financial Figures

• $0.0001 — 2,520 shares of common stock, par value $0.0001 per share ("common stock"), together wi
• $4.92 — sumed combined public offering price of $4.92 per share and accompanying Warrants, wh
• $0.125 — hare under Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of common stock underly
• $4 — ther with the accompanying Warrants, is $4.9199, which is equal to the closing pri
• $4.9199 — per share and accompanying Warrants and $4.9199 per Pre-Funded Warrant and accompanying
• $50,000 — accountable expenses in an amount up to $50,000, legal fees and expenses and other out-
• $100,000 — -pocket expenses in the amount of up to $100,000, road show expenses in the amount of up
• $5,000 — ad show expenses in the amount of up to $5,000, and for its clearing expenses in the a
• $15,950 — s clearing expenses in the amount up to $15,950. For a description of compensation to b

Filing Documents

• ny20052513x3_s1.htm (S-1) — 463KB
• ny20052513x3_ex4-19.htm (EX-4.19) — 100KB
• ny20052513x3_ex4-20.htm (EX-4.20) — 110KB
• ny20052513x3_ex5-1.htm (EX-5.1) — 22KB
• ny20052513x3_ex10-24.htm (EX-10.24) — 221KB
• ny20052513x3_ex23-1.htm (EX-23.1) — 2KB
• ny20052513x3_exfee.htm (EX-FILING FEES) — 35KB
• logo_bionano02.jpg (GRAPHIC) — 25KB
• logo_bionano02x1.jpg (GRAPHIC) — 58KB
• ny20052513x3_ex5-1logo.jpg (GRAPHIC) — 358KB
• 0001140361-25-034651.txt ( ) — 1719KB
• ny20052513x3_exfee_htm.xml (XML) — 18KB

USE OF PROCEEDS

USE OF PROCEEDS 9 DIVIDEND POLICY 10

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 11

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 14 PLAN OF DISTRIBUTION 18 INFORMATION INCORPORATED BY REFERENCE 21 WHERE YOU CAN FIND MORE INFORMATION 22 LEGAL MATTERS 23 EXPERTS 23 i TABLE OF CONTENTS ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under "Where You Can Find More Information." You should carefully read this prospectus as well as additional information described under "Information Incorporated by Reference," before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to b

View Full Filing

View this S-1 filing on SEC EDGAR